TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer
Pharmaceutics · 09.11.2026 · 18 (11) · 1448
DOI: 10.3390/pharmaceutics18111448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 09.11.2026. Verfasst von Yifan Liu und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China, the Guangdong Provincial Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund.
Abstract (Originalsprache)
Background
Tumor necrosis factor receptor 2 (TNFR2) is a pivotal immune checkpoint that is highly expressed within the immunosuppressive tumor microenvironment (TME), particularly on regulatory T cells (Tregs). The P20 peptide specifically binds TNFR2, but its rapid enzymatic degradation in vivo severely limits its clinical translation as an imaging tracer.
Methods
Here, we developed a P20-conjugated lipid nanoprobe (DPP) via thin-film hydration and systematically evaluated its physicochemical properties, receptor-binding specificity, biosafety, and in vivo positron emission tomography (PET)/computed tomography (CT) imaging performance in male C57BL/6J mice bearing subcutaneous MC38 wild-type (WT) or TNFR2-knockout (KO) colon tumors.
Results
DPP exhibited a near-spherical morphology, a predominant particle-size distribution peak at approximately 125.6 nm, a negative surface charge, and relatively stable hydrodynamic diameters over 7 days. In vitro assays supported TNFR2-associated cellular recognition and showed negligible cytotoxicity under the tested conditions. Micro-PET/CT imaging revealed that DPP markedly improved tumor retention (tumor SUVmean at 4 h: 0.577 ± 0.314) compared with free P20 (SUVmean at 4 h: 0.065 ± 0.011; n = 6 per group; two-sided Welch’s unpaired t-test with Benjamini–Hochberg correction, adjusted q = 0.010298) in MC38-WT tumors. Tumor SUVmean was higher in WT than in KO tumors at 7 h (0.677 ± 0.181 vs. 0.381 ± 0.191; p = 0.02942) and 12 h (0.428 ± 0.121 vs. 0.224 ± 0.108; p = 0.01588), with both adjusted q values equal to 0.05885 (n = 6 and n = 5, respectively). Notably, tumor-to-muscle uptake ratios were also higher in WT tumors at 7 h (13.11 ± 5.10 vs. 6.86 ± 2.97; p = 0.03459; adjusted q = 0.13836).
Conclusions
These results demonstrate that the liposomal formulation enhances tumor-associated uptake of the P20-based tracer, while TNFR2-dependent uptake and the non-invasive monitoring of Treg compartments remain to be validated.
Förderung
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
- the Guangdong Provincial Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund
- the National Key R&D Program of China
- the Key Realm R&D Program of Guangdong Province
- Macao Science and Technology Development Fund
- Leading Yang Technology (Shenzhen) Co., Ltd.
- Guangdong Provincial Basic and Applied Basic Research Fund Provincial Enterprise Joint Fund
Zitieren
APA
Liu, Y., Xu, Y., Yu, W., Gao, C., Wu, S., Jin, H., & Xu, M. (2026). TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer. Pharmaceutics, 18(11), 1448. https://doi.org/10.3390/pharmaceutics18111448
Vancouver
Liu Y, Xu Y, Yu W, Gao C, Wu S, Jin H, et al. TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer. Pharmaceutics. 2026;18(11):1448. doi:10.3390/pharmaceutics18111448
BibTeX
@article{Liu2026,
author = {Liu, Yifan and Xu, Yanjun and Yu, Wenrong and Gao, Chenxi and Wu, Sirui and Jin, Hongjun and Xu, Mengze},
title = {TNFR2-Specific P20 Peptide-Conjugated Lipid Nanoprobe Enables Dual-Modal PET/CT Molecular Imaging for Precise Detection of Colon Cancer},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1448},
doi = {10.3390/pharmaceutics18111448}
}
EUVIMED